IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• IDEXX Laboratories has a consensus analyst rating of “Moderate Buy” from 10 brokerages, with six buy ratings and four hold ratings. The average 1-year price target is $751.
• The company recently reported strong quarterly results, posting EPS of $3.47 versus expectations of $3.41 and revenue of $1.14 billion, both ahead of estimates. Revenue also rose 14.3% year over year.
• Despite the positive earnings beat, the stock was trading at $552.46, below its 200-day average of $597.62 and far under its 1-year high of $769.98. Institutional ownership remains high at 87.84%.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $751.00.

IDXX has been the topic of a number of research analyst reports. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price on the stock. Weiss Ratings downgraded IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Tuesday, July 14th. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Finally, Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds have recently made changes to their positions in IDXX. Generali Investments Management Co LLC lifted its stake in IDEXX Laboratories by 40.9% in the 2nd quarter. Generali Investments Management Co LLC now owns 902 shares of the company's stock valued at $475,000 after purchasing an additional 262 shares during the last quarter. E. Ohman J or Asset Management AB grew its stake in shares of IDEXX Laboratories by 11.1% during the second quarter. E. Ohman J or Asset Management AB now owns 3,911 shares of the company's stock worth $2,059,000 after buying an additional 390 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of IDEXX Laboratories by 5.9% during the second quarter. Handelsbanken Fonder AB now owns 38,344 shares of the company's stock worth $20,186,000 after buying an additional 2,150 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of IDEXX Laboratories by 7.6% during the second quarter. Revolve Wealth Partners LLC now owns 963 shares of the company's stock worth $507,000 after buying an additional 68 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC lifted its stake in shares of IDEXX Laboratories by 29.8% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 488 shares of the company's stock valued at $257,000 after acquiring an additional 112 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $552.46 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $43.58 billion, a PE ratio of 40.68, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. The company has a 50 day moving average of $555.50 and a 200-day moving average of $597.62. IDEXX Laboratories has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period last year, the firm posted $2.91 earnings per share. The firm's quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.